In good accordance with our current discoveries regarding M344, data by Laschanzky et al. demonstrated that inhibition of HDACs 1, 2, and 6 by other HDAC inhibitors effectively complements the therapeutic effects of gemcitabine against pancreatic cancer [14]. This evidence concerns the gene HDAC9 and familial pancreatic carcinoma.